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Background: Phenotypic profiling of knockout libraries is a possible functional genomics strategy.
Results:Gluconate excretion is a novel phenotype of the Pseudomonas aeruginosa rpoNmutant, which is also weakly associated
with antibiotic susceptibility in a clinical strain panel.
Conclusion: The rpoN phenotype results from catabolite repression deregulation of 6-phosphogluconate dehydratase.
Significance: NMR profiling can uncover novel gene functions with potential clinical relevance.
Metabolic footprinting of supernatants has been proposed as
a tool for assigning gene function. We used NMR spectroscopy
to measure the exometabolome of 86 single-gene transposon
insertion mutant strains (mutants from central carbonmetabo-
lism and regulatory mutants) of the opportunistic pathogen
Pseudomonas aeruginosa, grown on a medium designed to rep-
resent the nutritional content of cystic fibrosis sputum. Func-
tionally related genes had similar metabolic profiles. E.g. for
two-component system mutants, the cognate response regula-
tor and sensor kinase genes clustered tightly together. Some
strains had metabolic phenotypes (metabotypes) that could be
related to the known gene function. E.g. pyruvate dehydrogen-
ase mutants accumulated large amounts of pyruvate in the
medium. In other cases, themetabolic phenotypes were not eas-
ily interpretable. The rpoN mutant, which lacks the alternative
 factor RpoN (54), accumulated high levels of gluconate in the
medium. In addition, endometabolomeprofilingof intracellular
metabolites identified a number of systemic metabolic changes.
We linked this to indirect regulation of the catabolite repression
protein Crc via the non-coding RNA crcZ and found that a crcZ
(but not crc) mutant also shared the high-gluconate phenotype.
Weprofiled an additional set of relevantmetabolic enzymes and
transporters, including Crc targets, and showed that the Crc-
regulated eddmutant (gluconate-6-phosphate dehydratase) had
similar gluconate levels as the rpoN mutant. Finally, a set of
clinical isolates showed patient- and random amplification of
polymorphic DNA (RAPD) type-specific differences in gluco-
nate production, which were associated significantly with resis-
tance across four antibiotics (tobramycin, ciprofloxacin, aztreo-
nam, and imipenem), indicating that this has potential clinical
relevance.
Pseudomonas aeruginosa is an ecologically versatile, Gram-
negative bacterium, and some of this versatility is undoubtedly
due to its ability to use a wide range of different compounds as
energy sources for growth. It does not normally cause disease in
healthy human adults, but can infect cuts and burns. It also
frequently forms chronic infections in the lungs of cystic fibro-
sis (CF)3 patients. CF is a genetic disease caused by mutation of
the cystic fibrosis transmembrane conductance regulator, a
chloride ion transporter, that leads to an ionic imbalance across
the apical surface of epithelial cells and a dehydrated airway
surface that impairs mucociliatory clearance. This offers an
opportunity for bacterial colonization, and CF patients typi-
cally have a wide range of different colonizing bacteria (1).
However, the majority of CF patients eventually become
infected with P. aeruginosa, which is very difficult to eradicate
from the CF lung once established and typically forms life-long
chronic infections. The majority of CF patients ultimately die
from respiratory failure caused by the cycle of infection, inflam-
mation, and tissue damage brought on by this (2). Understand-
ing how P. aeruginosa adapts to the changing nutritional and
physical environment of the CF lung as well as the presence of
competing microbes is important to understand the ecology of
this infection. Some genetic adaptations of P. aeruginosa have
been identified during its chronic infection of the CF lung, but
further knowledge of these and other aspects of the biology of
this versatile bacteriumwill improve understanding of its infec-
tion biology as well as basic aspects of its gene function and
physiology.
The compendium approach has been influential in the post-
genomic era. The basic concept is that compendia of pheno-
typic profiles, such as those generated by transcriptional
microarrays, can be used to classify single-gene knockout
strains on the basis that functionally related geneswould cluster
together (3). This approach is not restricted to transcriptomic
data. The same approach can be applied to metabolomic pro-* Thisworkwas supportedby theWellcomeTrust (reference 093612/Z/41/Z).
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files. Indeed, it has been argued that there are advantages to
using metabolome rather than transcriptome data, as meta-
bolic control analysis predicts that single-gene knockouts are
likely to have larger changes inmetabolite than transcript levels
(4). The experimental evidence to date is compatible with this,
and the metabolic effects of gene deletion are clearly greater
than the effects of altering growth rate (5). There are also
advantages to analyzing the exometabolome of cells, or meta-
bolic footprinting (6). These are both procedural (the separa-
tion of medium from the cells is straightforward, and the accu-
mulatedmetabolic changes are effectively integrated over time)
and biological (as the extracellularmedium is not under cellular
homeostatic control, metabolites can accumulate to high lev-
els). P. aeruginosa has a whole-genome knockout library avail-
able (PA14NR) (7). Previous functional genomic studies with
this library have focused on simple phenotypic endpoints
(such as growth) under multiple conditions (8–10). These
approaches to characterizing “phenotypic landscapes” can be
very powerful (11, 12), but it would also be valuable to compare
the compendium approach on the basis of information-rich
complex phenotypes.
Here we investigated the feasibility of using ametabolic foot-
printing approach to characterize large sample sets like whole-
genome knockout libraries. As a proof-of-principle study, we
carried out metabolic footprinting by NMR spectroscopy on a
subset of 86 mutant strains of P. aeruginosa, chosen to repre-
sent a range of targets, includingmetabolic enzymes, transcrip-
tional regulators, two-component systems, and quorum sens-
ing pathways. We then analyzed the exometabolome of cells
grown on synthetic cystic fibrosis medium (SCFM), a defined
medium that is designed to mimic the metabolic composition
of CF sputum (13). Finally, we tested a novel phenotype (gluco-
nate excretion) in a number of CF clinical isolates and its rela-
tion to antibiotic susceptibility.
EXPERIMENTAL PROCEDURES
Strains and Growth Conditions—The deletion library strains
were taken from PA14NR, created by Liberati et al. (7), in a
PA14 background. We chose 86 of these strains. The full list is
given in supplemental Table S1. For the characterization of the
rpoN mutation and the crc and crcZ genes, we received an in-
frame deletionmutant and complementedmutant strain in the
PAO1 background fromD.Haas (University of Lausanne, Swit-
zerland). To account for the functional glutamine auxotrophy
(14), we supplemented the growth media for all experiments
containing the rpoN mutant with 2 mM glutamine. All strains
were grown in 1 ml of SCFM (13) in 96-well deep-well plates
sealed with oxygen-permeable membranes to allow gas trans-
fer. Samples were taken after 24 h by centrifuging the plates and
transferring the supernatants to a new deep-well plate. Experi-
ments were carried out with five biological replicates.
NMR Spectroscopy—We prepared samples for NMR by mix-
ing 0.8 ml of cell supernatant with 0.2 ml of NMR buffer. The
NMR buffer contained 3.3 mM sodium trimethylsilyl-2H6-pro-
panesulfonic acid and 24 mMNaN3 in 2H2O, resulting in a final
concentration in each sample of 0.66 and 4.8 mM, respectively.
We acquired the spectra on a Bruker DRX600 Avance spec-
trometer (Bruker Biospin, Rheinstetten, Germany) with a mag-
netic field strength of 14.1 tesla and 600MHz proton resonance
frequency, equipped with a 4-mm flow probe. The samples
were held at 300 K during acquisition and were introduced
using a Gilson robot flow-injection autosampler. A sample
volume of 0.7 ml was injected onto the flow probe, with three
probe wash steps between every sample. The samples were
injected in the order that they were cultured in 96-well plates,
and five replicate plates were injected in turn. Spectra were
acquired using a one-dimensional solvent-suppressed se-
quence essentially as described by Beckonert et al. (15).
Metabolite assignmentswere on the basis ofmatching chem-
ical shifts and multiplicities to online databases such as the
Human Metabolome Database (16) and the Biological Mag-
netic Resonance Bank (17) and by using the proprietary NMR
Suite database (Chenomx, Alberta, Canada). Assignment of
pyruvate, 2,2-dihydropropanoate and gluconate was con-
firmed by acquiring two-dimensional heteronuclear single
quantum coherence spectra.
NMR Data Processing—The data were initially processed in
iNMR 3 (Nucleomatica, Molfetta, Italy). The free induction
decays were zero-filled by a factor of 1.5 and multiplied by an
exponential apodization factor equivalent to 1 Hz line broad-
ening, followed by Fourier transform. Phase correction, base-
line correction, and referencing chemical shifts to sodium trim-
ethylsilyl-2H6-propanesulfonic acid (  0) were carried out
using the proprietary algorithms of the software, and the spec-
tra were exported as ASCII files and imported into Matlab. For
first-pass data analysis, the spectra were then aligned following
themethod of Veselkov et al. (18), and integral boundaries were
chosen manually so that, as far as possible, each resonance was
represented by a single integral, and all resonances across the
set of spectra were included. In many cases, integrals included
contributions frommore than one metabolite because of over-
lapping resonances. The spectra were then reprocessed for a
more in-depth analysis by fitting individual metabolites to the
spectra using the R package BATMAN, which uses a Bayesian
approach to deconvolve one-dimensional spectra into a mix-
ture of Lorentzian functions with wavelet functions used to fit
residual intensity (19, 20). The spectra were ordered with
respect to pH to improve peak identification (21).
Gluconate Assay—We used a commercial enzymatic gluco-
nate assay (Megazyme Ltd., Ireland). The assay was carried out
according to the instructions of the manufacturer, except that
we converted it to a 96-well-plate format by reducing the reac-
tion mixture volume to 20 l of reaction buffer, 20 l of
NADP/ATP solution, 2 l of 6-phosphogluconate dehydro-
genase suspension, 2l of gluconate kinase suspension, and 100
l of bacterial supernatant. The assay was linear between 5 and
1250 M gluconate.
Oxygen Consumption Assay—We grew 50-ml cultures of the
PA14wild-type strain and the rpoNmutant and harvested them
by centrifugation (3000 g, 30min) when they reached anA600
of between 0.3 and 0.8. The pelleted cells were washed in 20 ml
of phosphate buffer (pH 7), resuspended in 500l of phosphate
buffer, and kept on ice. An oxygen electrode was equilibrated
with 3 ml of phosphate buffer (pH 7) and maintained at 30 °C.
Briefly, 100l of cells was added to 3ml of phosphate buffer on
the electrode, and the signal response was recorded on a chart
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recorder for 3 min to establish a base-line oxygen concentra-
tion. For each sample, 30 l of either 1 M glucose or 1 M gluco-
nate was then added, and the signal responsewas recorded for 3
min to establish the rate of oxygen consumption associated
with glucose or gluconate dehydrogenase, respectively. The
base-line rate of oxygen consumption was subtracted from the
rate following addition of either glucose or gluconate. Oxygen
consumption rates were then normalized to protein concentra-
tion for each sample, which was determined using a modified
Lowry procedure (22).
Substrate Utilization Profiling—We used the commercial
Biolog “phenotype microarray” system (23) to profile the wild-
type and rpoNmutant strains (on a PA14 background) with the
plates PM1, PM2A, and PM3B containing 190 separate sole
carbon source and 95 separate sole nitrogen source substrates
(Technopath, Ballina, Ireland). Briefly, cells were grown as pre-
culture in M9  glucose  glutamine to optical densities of
0.6–0.8. At this optical density, 2 ml of cells were harvested,
washed with quarter-strength microbiological Ringer’s solu-
tion, and resuspended in 10 ml of inoculation medium (M9
salts). For carbon plates, the inoculation medium contained
NH4Cl and glutamine, and for PM3B, it contained glucose and
glutamine. Cells were grown for 24 h, after which the optical
density at 595 and 750 nmwas recorded. The 750-nm reading is
a measurement of general turbidity, whereas 595 nm is the
absorption maximum of the reduced dye.
Metabolite Profiling Using GC-MS—We analyzed the endo-
metabolomeof thewild-type, rpoN, and complementedmutant
on the PAO1 background. The cells were sampled (n  6) by
rapid filtration using a method adapted from Bolten et al. (24).
Briefly, 2.5 ml of culture was harvested by vacuum filtration
(filter: polytetrafluoroethylene, 0.45-m pore size, 47 mm;
stand: magnetic filter funnel, Pall, Ann Arbor, MI) and washed
with 5 ml of 0.9% saline solution. The filter was transferred to a
50-ml reaction tube containing 10 ml of cold (40 °C) metha-
nol:acetonitrile:H2O (2:2:1, v/v/v) and frozen in liquid nitrogen.
Afterward, all extracts were subjected to two freeze-thaw cycles
and sonication. After the removal of the filter, the extracts were
centrifuged to pellet the cellular debris and dried in a vacuum
concentrator (Eppendorf, 45 °C). We derivatized the samples
by methoximation followed by trimethylsilylation, following
themethod of Kind et al. (25), and analyzed them on a 7890GC
coupled to a 5975c mass spectrometer (Agilent, UK). We ana-
lyzed the data by first processing all files with AMDIS using the
FiehnLib retention time-locked library (25). We then carried
out an additional step for manual inspection of all peaks across
all samples, withmanual adjustment of retention timewindows
where appropriate, and “back-filled” the samplematrix by rein-
tegrating the raw data so that every sample/peak combination
had a numerical value (26).
Measuring Antibiotic Susceptibility—We measured gluco-
nate production in 156 longitudinal isolates taken from 16
patients, in which each set of strains from a single patient rep-
resented a clonal lineage (27). We then chose a subset of 96 of
these isolates andmeasuredminimal inhibitory concentrations
of five different antibiotics (tobramycin, imipenem, ciprofloxa-
cin, colistin, and aztreonam) using Etest strips impregnated
with an antibiotic gradient (bioMérieux, Basingstoke, UK).
Genotypes as assessed by randomamplification of polymorphic
DNA (RAPD) typing (28) of these isolates were available from a
previous study (29).
RESULTS
Growth and Sampling—We selected a total of 86 mutants,
corresponding to 72 genes in total, as some genes were repre-
sented bymore than one insertion (supplemental Table S1).We
grew the bacterial strains in 1 ml of SCFM and sampled the
medium after 24 h of growth for exometabolome profiling.
Most of the strains alkalized the growth medium to some
extent (data not shown), and so there were pH-related shifts in
resonance frequencies between spectra. Because of this, using
simple peak integrals gave poor-quality data, and so we used a
peak-fitting deconvolution method to provide the best output.
Manual peak-fitting (“targeted profiling”) by a skilled spectros-
copist using computer-aided software such as Chenomx NMR
Suite (30) is highly precise (31), but is time-consuming and
therefore not feasible for projects with large numbers of spec-
tra.Weused the freely available RpackageBATMAN(19, 20) to
fit individual metabolites to the spectra, thus allowing for both
peak overlap and peak shifting. We manually inspected all of
the spectra tomake sure therewere no incorrectly fittedmetab-
olites. The results were quantitatively comparable with the de
facto gold standard Chenomx data when compared for a repre-
sentative sample of spectra (data not shown). We quantified 25
metabolites from the spectra, eight of which were excreted by
some or all of the strains and 17 of which were present in the
original medium and consumed to varying degrees. All of the
data are available for downloading (supplemental Table S2).
Five of the eight excreted metabolites were assigned (ethanol,
formate, acetate, pyruvate, and gluconate), and we also quanti-
fied three unassigned resonances ( 1.06 ppm (doublet),  2.47
ppm (singlet), and  4.44 ppm (singlet)).
Biological Validation by Functional Clustering—We wanted
to determine whether NMR exometabolome data would be
useful for clustering knockout mutants of related function, and
so carried out an initial analysis on whole profiles. Principal
component analysis is a robust, unsupervised, multivariate
technique that is often used for dimension reduction and data
visualization. Principal component analysis alonewas sufficient
to show that strain replicates clustered tightly together, indicat-
ing good biological reproducibility (Fig. 1). The majority of the
mutants grew to similar final A600 as the wild type (Fig. 2), but
some strains had clear growth defects. The two tpiA mutants
and putative acoA mutant did not grow, whereas the rpoN,
aceE, and aceFmutants hadmoderate to severe growth defects.
A number of strains grew to higher final densities than the wild
type, with sixmutants reachingA600 of greater than 120% of the
wild type. PC1 could be interpreted as an overall growth axis.
PC1 scores were highly correlated to A600 (R2  0.82, p 
0.0001). On PC2, the aceE, aceF, as well as rpoN clustered away
from the majority of the strains (Fig. 1).
We followed the approach of Raamsdonk et al. (4) in using
linear discriminant analysis, which is supervised in the sense
that it attempts to separate all strains in the biochemical space
but unsupervised with respect to any knowledge of which
strains are similar. Hence, if two strains cluster together follow-
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ing linear discriminant analysis, it can be interpreted as an
unsupervised indication that the strains have a similar metab-
olism. Furthermore, this could be used to disentangle strain-
specific changes from the overall effects of growth. Principal
component analysis can be used as a dimension reduction pre-
processing step for linear discriminant analysis, and excluding
PC1 effectively removes the growth-related information. Using
all the data as an input, the aceE and aceF strainswere separated
from the rest along axis 1, and rpoNwas separated from the rest
along axis 2 (data not shown). This remained true even when
using the first 10 PC scores as input but excluding PC1 (Fig. 1).
In addition, we focused on two-component systems. These
bacterial regulatory systems prototypically comprise a mem-
brane-localized histidine sensor kinase and a cytoplasmically
localized response regulator (32). They have low levels of cross-
talk (33), so they can be used for biological validation (i.e. do
kinase and regulator pairs cluster together?). We clustered the
two-component system mutants separately on the basis of
Euclidean distance. The kinase/regulator pairs formed separate
clusters when there were significant differences from the wild
type, i.e. for the cbrA/cbrB and fleR/fleS pairs (Fig. 1). Presum-
ably the other genes were not expressed under these growth
conditions. Together, all of these observations provide a biolog-
ical validation that functionally related strains clustered
together.
Metabolic Effects of Mutations—We then examined the data
in more depth to get a more specific idea of which metabolites
were altered and for which strains (Fig. 2). Alanine, lactate,
phenylalanine, and glutamate were strongly negatively corre-
lated with growth. I.e. lower levels in the supernatant (and
therefore elevated compound uptake) coincided with higher
optical densities. This is obvious by eye when examining the
data sorted byA600 (e.g. for alanine, Fig. 2C). Lactate is themajor
carbon source in SCFM, and lactate utilization and growthwere
strongly correlated across most strains. Some strains, however,
most notably strains withmutations in genes encoding for quo-
rum sensingmolecule synthesis (rhlI, lasI, pqsA, and pqsH), had
inefficient lactate use. These strains consumed almost all the
lactate from the medium but did not grow to the OD600 that
would have been expected (data not shown). The only other
strains with equally inefficient lactate utilization were mutants
deficient in RsmA and DksA, both negative regulators of quo-
rum sensing (34–36).
Two of the excreted metabolites were present at very high
levels in some strains: gluconate and pyruvate. Pyruvate was
excreted by the aceE and aceF mutants, respectively, whereas
gluconate was mainly produced by the rpoN, cbrA, and cbrB
mutants and was highest in the rpoNmutant in particular (Fig.
2).We validated this observation independently by carrying out
an enzymatic gluconate quantification of all samples. This con-
firmed the NMR results, with the rpoN strain samples again
with the highest gluconate production (data not shown). Glu-
conate production has not been described as an RpoN-depen-
dent phenotype that we are aware of, and so we wanted to con-
firm that this was a genuine effect of the rpoNmutation and not
a downstream effect of the transposon insertion or secondary
mutations. We measured growth and gluconate for samples
grown in standard shake flasks, both for the library rpoN trans-
poson mutant and the PA14 wild type as well as for a clean
in-frame rpoNdeletionmutant in the PAO1background and its
isogenic parent strain. We supplemented the medium with 2
mM glutamine to make sure that any phenotype was not a sim-
ple consequence of glutamine auxotrophy (37). Growth was
decreased, and gluconate was elevated in both backgrounds
(Fig. 3), and so we conclude that gluconate production is a
reproducible RpoN-defective phenotype.
Characterization of the rpoN Mutation—To further charac-
terize the pleiotropic effects of the rpoNmutation, we analyzed
the metabolic capacity of the rpoNmutant and its parent strain
using the phenotypic microarray system from Biolog (Techno-
path). This technology measures microbial activity using a
redox-active dye in a 96-well format, with each plate containing
95 different conditions (23). We investigated activity on 190
different sole carbon sources (using glutamine as a nitrogen
source) and 95 different sole nitrogen sources (using glucose as
a carbon source). This confirmed the key role of rpoN in nitro-
FIGURE1.Functionally relatedP. aeruginosa strainsaremetabolically similar.A, principal component analysis scoreplotof all strains, PCs1and2.Different
colors represent differentmutant strains, and the lines connect individual points to strain centroids. B, linear discriminant analysis of dimension-reduced data
(PCs 2–10 inclusive). Ellipses represent 95% confidence intervals for strains. C, hierarchical cluster analysis of mean concentrations for two-component system
mutants.
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FIGURE 2.Metabolite changes inP. aeruginosamutants.A, metabolite levels for all strains (data normalized tomedians). B, growthof allmutants (as percent
of the wild type). C, alanine utilization increases with extent of growth. In the “sunburst” plot, each ray represents a single sample. Differentmutant strains are
indicated by different colors and are sorted clockwise according to increasing A600. The blue circle indicates the original level in SCFM, the red circle represents
themean final level, and the black circle themedian final level across all strains.D, aceE and aceF strains have high levels of pyruvate excretion. E, the rpoN strain
produces high levels of gluconate and the cbrA strain the next highest.
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gen metabolism, with the mutant only able to utilize 23 nitro-
gen sources, whereas the wild type utilized 52. Surprisingly, the
rpoN mutant exhibited a higher activity than the wild type on
many of the carbon sources, with detectable activity on 117 and
75 carbon sources, respectively (supplemental Table S3).
We also looked at the intracellular metabolome (endo-
metabolome) of the rpoN clean deletionmutant, reanalyzed the
supernatants (exometabolome) in more detail, and compared
the profiles to thewild type and a complementedmutant strain.
To this end, we grew the strains in SCFM in shake flasks, sam-
pled them at 5 h and 24 h by rapid filtration, and analyzed the
endometabolome byGC-MS and the exometabolome byNMR.
The metabolic effects of the rpoN mutation were both wide-
ranging and growth phase-dependent (Fig. 4). The exometabo-
lome data showed that organic acid production is altered in the
rpoNmutant, which produced more gluconate but less acetate
levels than the WT after 5 h. In addition, proline and serine
utilization was reduced beyond what would be expected for
the lower growth rate. In contrast, glucose utilization was
increased. After 24 h, most metabolites were used up, but the
rpoNmutant failed to utilize all of the available histidine (data
not shown).
After 5 h of growth, the main endometabolome phenotypes
included deregulation of central sugar metabolism (higher lev-
els of gluconate and lower levels of glucose-6-phosphate) as
well as citric acid cycle metabolites (lower levels of citrate and
-ketoglutarate). After 24 h of growth, more significant differ-
ences could be observed, with amino acid metabolism and the
citric acid cycle particularly affected (Fig. 4). The rpoNmutant
also contained significantly lower levels of disaccharides such
as trehalose and sucrose. However, few metabolites showed
consistent differences across both time-points.Only citrate and
4-hydroxyphenylacetate had consistently lower levels (data not
shown). The effect on 4-hydroxyphenylacetate suggests a pos-
sible role for RpoN in regulating the conversion of phenylala-
nine and tyrosine. This is further strengthened by the fact that
the tyrosine/phenylalanine ratio was about 10 times higher in
the rpoN mutant than in the wild type and complemented
strains after 24 h of growth (data not shown).
Gluconate Production—Why do RpoN-deficient strains
excrete gluconate? The presence of a compound in the culture
medium can in general be the result of either the active excre-
tion of the compound or the extracellular conversion of a sub-
strate coupled to the inability to take up the resulting com-
pound quickly enough. Both scenarios can be brought about by
the deregulation ofmetabolic enzymes ormetabolite transport-
ers. To narrow down the reason for gluconate production by
the rpoN mutant, we looked at the kinetics of gluconate pro-
duction in shake flask culture. Gluconate production peaked at
around 6–7 h in both SCFM as well as minimal glucose
medium, with a much higher concentration on the glucose
medium (Fig. 5). This could potentially be due to gluconate
reuptake, but theNMR spectra of supernatants of both cultures
showed the production of 2-ketogluconate at similar signal
intensities (data not shown). Therefore, a major part of the
decrease in gluconate concentration in stationary phase was
not due to direct uptake by the cell but to conversion to 2-
ketogluconate. Glucose is oxidized to gluconate in the
periplasm by a membrane-bound glucose dehydrogenase
(GDH), and further oxidation to 2-ketogluconate is carried out
by a membrane-bound gluconate dehydrogenase (38). To elu-
cidate whether the increase in gluconate and 2-ketogluconate
was caused by decreased uptake or by deregulation of the met-
abolic enzymes, we measured the activity of both GDH and
gluconate dehydrogenase. Gluconate dehydrogenase was not
altered, but GDH was clearly deregulated, with more than
5-fold higher activity for the rpoN mutant compared with the
WT (Fig. 3).
This does not, however, fully explain the gluconate accumu-
lation, as GDHdoes not have an RpoN binding site4. Gluconate
was also increased (although to a lesser degree than for rpoN) in
the cbrA and cbrB knockout strains (Fig. 2). Both RpoN and
CbrA/CbrB have been reported as positive regulators of the
non-coding small regulatory RNA crcZ.This binds to the catab-
olite repression protein Crc which, in turn, regulates specific
metabolic genes by binding to their mRNA transcripts, reduc-
ing translation (39). Hence, we predicted that the crcZ knock-
out strain should also show an increase in gluconate production
but the crc knockout should not. We obtained both of the
knockouts in a PAO1 background and tested them using the
gluconate assay. This confirmed our hypothesis. The crcZ
knockout strain produced significantlymore levels of gluconate
than the wild type, but the crc knockout was not different from
the wild type (Fig. 6).
We then asked whether a specific Crc target mediated this
effect. Glucose, gluconate, and 2-ketogluconate can be
imported through the cytoplasmic membrane by dedicated
transporters where they are then phosphorylated by glucoki-
nase, gluconokinase, or 2-ketogluconokinase, respectively.
Glucose 6-phosphate and 2-ketogluconate 6-phosphate are
further converted to 6-phosphogluconate, which funnels the
carbon into the Entner-Douderoff pathway. Several of these
genes have Crc binding sites, and so we investigated gluconate
production for thesemutants (and other adjacent enzymes) (23
4 D. Studholme, personal communication.
FIGURE 3. RpoN deletion decreases growth but increases gluconate
excretion in two different strain background (A). Œ and f, rpoN mutant
strains; ‚ and , wild-type strains; Œ and ‚, PA14 background; f and ,
PAO1 background. Bars showmean S.E., n 3. B, glucose dehydrogenase
but not gluconate dehydrogenase activity is deregulated in rpoN-mutant
strains.Bars showmeanS.E.,n3. Filledbars, rpoNmutant; emptybars, wild
type; ns, not significant.
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additional strains corresponding to 18 additional genes, supple-
mental Table S4). Only one of these, the edd mutant (6-phos-
phogluconate dehydratase (6PGDH)) produced extracellular
gluconate levels comparable with the rpoNmutant (Fig. 4). The
edd and rpoN gluconate concentrations were not significantly
different (p 0.17).
Clinical Relevance—Finally, we investigated whether gluco-
nate production from glucose might be of clinical relevance.
The CF lung is a nutritionally rich environment, and deregula-
tion of metabolic enzymes and rpoN mutations have been
reported for populations of clinical isolates (40–45). We pro-
filed gluconate production in a panel of 156 clinical isolates,
normalized to optical density. Twenty-five of these isolates had
significantly elevated gluconate production after 5 h of growth
in SCFMcomparedwith the PAO1 andPA14wild types (Fig. 7).
There was no evidence that gluconate production increased
with length of infection (data not shown), but the phenotype
was clearly patient-specific, with sets of isolates (i.e. clonal lin-
eages) from certain patients expressing high levels of gluconate
(p  0.001, Kruskal-Wallis test). Gluconate levels were also
significantly related to genotype, as measured by RAPD typing
(p 0.001, Kruskal-Wallis test, Fig. 7).
We then went on to measure antibiotic susceptibility in a
subset of 96 of these isolates (chosen so that there were six
isolates/patient on average) against five antibiotics. Four of the
five antibiotics showed clear significant differences between
patients and significant associationswith the length of infection
(data not shown). The fifth, colistin, did not show any signifi-
cant differences and was excluded from further analyses. We
then tested whether susceptibility was related to gluconate lev-
els using a linear model with log10(minimal inhibitory concen-
tration) as the dependent variable and “gluconate” and “anti-
biotic” as continuous and nominal independent variables,
respectively. The overall model was weak (R2adj  0.26) but
significant. Unsurprisingly, the choice of antibiotic had a highly
significant effect (p 0.0001, F 43.0). Gluconate production
was also significant (p 0.0031, F 8.9). (The interaction term
was not significant and was excluded from the model.) The
relationship with gluconate was positive so that high gluconate
producers tended to have higher log10(minimal inhibitory con-
centration), i.e. had reduced susceptibility to antibiotics.
DISCUSSION
ValidatingMetabolic Phenotypes—How can one validate the
results of this type of project without actually profiling the
entire library? There are two basic approaches: to interpret
the biochemical changes seen for individual knockouts and to
ask whether functionally related genes do, in fact, cluster
FIGURE 4. The 6-phosphogluconate dehydratase (edd mutant) is the only mutant with a Crc-binding motif tested that gives the same gluconate
accumulationphenotype as the rpoNmutant. Extracellular gluconate concentrations formutant strains are given by the size of the red dot in awhite square.
Additionally, exo- and endometabolome changes for the rpoNmutant are shown simultaneously in the samepathway context. Key given in inset. Gene names
are taken from the Pseudomonas genome database. An asterisk after the name indicates a predicted Crc-binding motif, taken from Browne et al. (56).
P. aeruginosaMetabolic Footprinting
15104 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 21•MAY 24, 2013
 at Im









together (the “FANCY” approach, or functional analysis by cor-
related responses (4, 6, 46)). We employed both of these meth-
ods. There was one obvious case that fulfilled both criteria. The
aceE and aceF genes encode subunits of the pyruvate dehydro-
genase complex, clustered together in multivariate analyses,
and bothmutants had very high concentrations of pyruvate and
2,2-dihydropropanoate (produced abiotically from pyruvate
(47)) in the supernatant. (The 2,2-dihydropropanoate peak
was not fitted but is detectable by simple inspection of the aceE
and aceF spectra.) However, acoB, acoC, PA14_19900, and
pdhB are also annotated as putative pyruvate dehydrogenase
subunits for P. aeruginosa PA14 (48). None of these mutants
exhibited a strong pyruvate excretion phenotype, suggesting
that these alternative pyruvate dehydrogenases are not actually
essential to pyruvate dehydrogenase activity either because
they are misassigned for function or were not expressed for
P. aeruginosa grown in SCFM.
In addition, the two-component system mutants clustered
kinase and regulator pairs together where any phenotype was
seen, suggesting this could be a relatively simple way to assign
“orphan” kinases. This also demonstrates a drawback of this
kind of approach. Three of the five pairs did not show any par-
ticular phenotype, presumably because the genes were not
expressed under the growth conditions. Indeed, for all mutants
we looked at, the most distinctive metabolic phenotypes were
observed for strains that also hadmarked growth defects (aceE,
aceF, rpoN). This highlights an important point. There is never
just one metabolic phenotype of a mutant, as phenotypes are
always context-dependent. Extending the footprinting
approach to the whole library would, therefore, probably give
FIGURE 5. Extracellular gluconate peaks during growth and declines in
stationary phase. A, synthetic cystic fibrosis medium. B, minimal medium
with glucose as the sole carbon source. Line plots represent growth (left axis)
and bars indicate extracellular gluconate production (right axis). Error bars
represent S.E. (n 3). f, wild type;, rpoNmutant.
FIGURE6.Gluconateproduction is regulatedby thenoncodingsmallRNA
crcZ. A, schematic regulatory network of Crc in P. aeruginosa. Relevant Crc
targets are shown, but this does not represent all possible targets: transport-
ers/permeases (i) andmetabolic enzymes (ii). Gluconate is increased for rpoN
and cbrA/Bmutants, so is predicted tobe increased for crcZ andunaffectedby
crc mutation. B, gluconate levels in mid-exponential phase for PAO1 wild-
type, a crcZmutant, and a crcmutant strain. Gluconate levels were quantified
by enzymatic assay (data are mean S.E., n 3) and were significantly dif-
ferent (p 0.05) between the WT and crcZ deletion strain (Welch’s t test).
FIGURE 7. Clinical isolates from different cystic fibrosis patients produce
different amounts of gluconate. The strains were grown for 5 h, and gluco-
natewas quantified by enzymatic assay. Each point represents themean glu-
conate level for an individual strain (n  3). The center line of the diamond
represents the patient mean, and the vertices of the diamond represent
mean  95% confidence intervals. The solid gray line indicates gluconate
production for rpoN-mutant PA14, and the dashed gray line indicates gluco-
nate production for wild-type PA14. A, gluconate production by different
strains from 16 individual patients (P01-P16). B, gluconate production by dif-
ferent RAPD types (only those types with a minimum of four strains are
shown).
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strong metabolic phenotypes for a relatively small percentage
of strains if using just one growth medium. This brings up a
second important point. The phenotypes we saw for the
growth-restrictedmutants were qualitatively different (appear-
ance of unexpected metabolites in the medium) and not just a
function of lack of utilization of the original metabolites pres-
ent. However, this overall extent-of-growth phenotype was the
main source of variation in the overall dataset on the basis of the
highly significant correlation of PC1 with A600. Is this kind of
metabolic phenotype biologically meaningful, or is it just a triv-
ial observation? Clearly it ismeaningful in the basic sense that it
encodes information on growth, but it is likely that it may
also potentially lead to mistaken hypotheses about functional
relatedness solely on the basis of shared growth patterns.
Using principal component analysis (or related multivariate
approaches) for dimension reduction, therefore, offers the
added benefit that this growth effect can be filtered out and the
results compared.
A so far unexplained observation was reduced efficiency of
lactate utilization by quorum sensing mutants, particularly as
this was true for both acyl homoserine lactone and Pseudomo-
nas quinolone signal systems and included negative regulators
as well as biosynthetic enzymes. This clearly requires further
investigation before any conclusions can be drawn, but is of
interest given the high concentrations of lactate in CF sputum.
Gluconate Excretion by rpoN Mutant Strains—RpoN is an
alternative  factor (54) that has roles in regulating flagellar
synthesis, motility, nitrogen transport, quorum sensing regula-
tion, and virulence, among others (49). Even though RpoN
function has been investigated extensively, gluconate produc-
tion has not, to our knowledge, been identified previously as a
phenotype for rpoNdeletion.We confirmed that the phenotype
was neither an artifact of the transposon insertion nor specific
to the PA14 background by acquiring a clean in-frame PAO1
deletion mutant. In both backgrounds and in two different
media, lack of rpoN led to a reduction in growth rate and pro-
duction of gluconate, which was then further converted to
2-ketogluconate.
Several metabolic phenotypes have already been described
for rpoNmutants, including the loss of ability to utilize various
carbon and nitrogen sources and amino acids (50, 51). RpoN is
also important for maintaining the C/N balance in Pseudomo-
nas (52–54). Our data are broadly, although not completely, in
agreement with these findings. The mutant showed reduced
activity onmost of the nitrogen sources tested and also failed to
grow on succinate, which is expected, because the succinate
transporter contains a RpoN binding motif. Interestingly, we
observed increased utilization for several carbon sources in
the Biolog plates. Because these have only been tested in the
microwell plate format using a redox dye, it remains to be seen
whether these observations would hold true for growth under
standard shake flask conditions.
Themetabolomic characterization of the rpoNmutant found
several additional phenotypes that occurred across different
metabolic pathways and were at least partly growth phase-de-
pendent. Citrate and 4-hydroxyphenylacetate were the only
metabolites that had consistent RpoN-dependent changes in
both exponential and stationary phase growth (5 h and 24 h).
The lower levels of citrate could be the result of increased isoci-
trate lyase activity, which was shown to be elevated in an rpoN
mutant ofP. aeruginosa (41). The higher level of 4-hydroxyphe-
nylacetate is probably linked to altered regulation of aromatic
amino acid metabolism. Previous studies have reported that an
aromatic amino acid transporter is also a Crc target (55).
Because of the pleiotropic effects of RpoN and the complex
regulation of central metabolism, it is not possible to provide
simple explanations (“just-so stories”) for all observed meta-
bolic changes. However, some of them can be attributed to
altered catabolite repression. Catabolite repression in P.
aeruginosa is different from the well studied Crp-mediated sys-
tem of enterobacteria. In E. coli, catabolite repression mainly
regulates sugar uptake, with glucose being the preferred sub-
strate, and is governedby the phosphorylation state of the phos-
photransferase system transporters (39, 56). In contrast, catab-
olite repression in Pseudomonas extends to amino and organic
acids (39), with data for P. aeruginosa and Pseudomonas putida
clearly showing a distinct hierarchy of metabolite uptake from
complex growthmedia (57, 58). Furthermore, although glucose
is the preferred substrate in enterobacteria, pseudomonads
preferentially take up citric acid cycle intermediates, such as
succinate, and certain amino acids, reflected by the poor corre-
lation between glucose uptake and growth shown in this study.
The Crc protein is a posttranscriptional inhibitor that controls
the expression of over 100 genes by binding to mRNA and pre-
venting translation (58, 59). The active levels of Crc are regu-
lated by CrcZ, a non-coding RNA that is under positive tran-
scriptional control by RpoN (60). A mutation in rpoN would
therefore result in lower CrcZ levels which, in turn, would lead
to deregulation of the proteins normally controlled by Crc.
Several of the phenotypes observed here could be due to
direct involvement of the Crc response. Proteins predicted to
be targets of Crc include the proline/sodium symporter (putP),
the lactate permease (lldP), and an alanine/sodium symporter
(56), and proline, lactate, and alanine levels were higher in rpoN
supernatants. Another target is phhA (phenylalanine-4-hydro-
lase), which converts phenylalanine to tyrosine, and intracellu-
lar aromatic amino acid concentrations were affected in the
mutant, indicating a deregulation of amino acid metabolism.
However, was the gluconate excretion phenotype regulated
via crcZ?A strong hintwas that gluconatewas also increased for
the cbrA/cbrB mutants, which, like RpoN, are positive regula-
tors of crcZ. We then confirmed this by analyzing crcZ and crc
knockouts. However, this still does not identify a specific target,
as there are several relevant genes in P. aeruginosa with Crc-
binding motifs, including both metabolite transporters and
metabolic enzymes (56). To follow this up,we screened an addi-
tional set of Crc-regulated mutants and found that 6PGDH
reproduced the RpoN phenotype. This has a directmechanistic
explanation. Metabolites upstream from 6PGDH accumulate
in the cell, and gluconate is exported to relieve this build-up. In
addition, glucose dehydrogenase activity is increased in the
rpoNmutant, which would tend to increase gluconate buildup
as well. However, we do not as yet have a direct explanation for
this observation. It is still possible that the regulation by Crc
could be more distributed. Perhaps knockdowns of multiple
transporters, for instance, would contribute to the extracellular
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gluconate build-up. However, given that the 6PGDH gluconate
excretion phenotype is not significantly different from the rpoN
mutant, it is clearly more parsimonious to conclude that the
effect is modulated via 6PGDH.
Clinical Relevance—It is known that P. aeruginosa rpoN
mutates sporadically in the CF lung, and this represents a
potential adaptation (45). Several clinical isolates were gluco-
nate producers when grown in SCFM, with significant differ-
ences between strains isolated from different patients. Further
studies could be carried out to investigate whether the isolates
are indeed rpoN mutants and whether rpoN mutations are
always linked to gluconate production or whether they are
compensated by secondary suppressor mutations, as shown for
mucA and alginate production (61, 62).
Although no obvious selective advantage was detected, i.e.
gluconate production was not associated with length of infec-
tion, there were differences between genotypes. Four of the
RAPD types were high gluconate producers, including the
A097 type that was seen inmultiple patients from the collecting
laboratory (29). However, the A002 type that was also found in
multiple patients was a low gluconate producer, so there is no
apparent relationship between potential transmissibility and
gluconate production.
Wemeasured susceptibility of a subset of the clinical isolates
to four antibiotics used in treating chronic P. aeruginosa CF
infections (63). This was significantly, although weakly, related
to gluconate production. Rapid forms of atmospheric pressure
mass spectrometry could potentially be used to assign bacterial
strains directly from patient samples such as sputum, without
culturing, for clinical diagnostics (64). It is easy to see how this
could be extended tomeasure bacterially producedmetabolites
in biofluids. Hence, although we do not claim that gluconate
productionwould be directly useful in a clinical setting, it serves
as proof of principle for how observations fromuntargeted pro-
filing experiments can ultimately be linked to clinically relevant
phenotypes. In general, context is increasingly seen as impor-
tant for antibiotic susceptibility of microbes with a realization
that there is no one Platonic value for resistance or sensitivity
for a particular strain (65). Understanding the interactions of
the metabolic network with antibiotic resistance is an impor-
tant future goal (66).
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